Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 6/2016

01-06-2016 | Original Article

Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus

Authors: Dora Sviben, Dubravko Forčić, Tihana Kurtović, Beata Halassy, Marija Brgles

Published in: Archives of Virology | Issue 6/2016

Login to get access

Abstract

Measles virus and mumps virus (MeV and MuV) are enveloped RNA viruses used for production of live attenuated vaccines for prophylaxis of measles and mumps disease, respectively. For biotechnological production of and basic research on these viruses, the preparation of highly purified and infectious viruses is a prerequisite, and to meet that aim, knowledge of their stability and biophysical properties is crucial. Our goal was to carry out a detailed investigation of the stability of MeV and MuV under various pH, temperature, shear stress, filtration and storage conditions, as well as to evaluate two commonly used purification techniques, ultracentrifugation and diafiltration, with regard to their efficiency and effect on virus properties. Virus titers were estimated by CCID50 assay, particle size and concentration were measured by Nanoparticle tracking analysis (NTA) measurements, and the host cell protein content was determined by ELISA. The results demonstrated the stability of MuV and MeV at pH <9 and above pH 4 and 5, respectively, and aggregation was observed at pH >9. Storage without stabilizer did not result in structural changes, but the reduction in infectivity after 24 hours was significant at +37 °C. Vortexing of the viruses resulted in significant particle degradation, leading to lower virus titers, whereas pipetting had much less impact on virus viability. Diafiltration resulted in higher recovery of both total and infectious virus particles than ultracentrifugation. These results provide important data for research on all upstream and downstream processes on these two viruses regarding biotechnological production and basic research.
Appendix
Available only for authorised users
Literature
1.
Lamb RA, Parks GD (2013) Paramixoviridae. In: Knipe DM, Howley PM (eds) Fields Virol, 6th edn. Lippincot Williams & Wilkins, Philadelphia, pp 957–995
2.
Daikoku E, Morita C, Kohno T, Sano K (2007) Analysis of morphology and infectivity of measles virus particles. Bull Osaka Med Coll 53:107–114
3.
Weiss K, Salzig D, Röder Y et al (2013) Influence of process conditions on measles virus stability. Am J Biochem Biotechnol 9:243–254CrossRef
4.
Ray BG, Swain RH (1954) An investigation of the mumps virus by electron microscopy. J Pathol Bacteriol 67:247–252CrossRefPubMed
5.
6.
Bose S, Song AS, Jardetzky TS, Lamb RA (2014) Fusion activation through attachment protein stalk domains indicates a conserved core mechanism of paramyxovirus entry into cells. J Virol 88:3925–3941CrossRefPubMedPubMedCentral
7.
8.
Weiss K, Salzig D, Mühlebach MD et al (2012) Key parameters of measles virus production for oncolytic virotherapy. Am J Biochem Biotechnol 8:81–98CrossRef
9.
10.
11.
Rapp F, Butel JS, Wallis C (1965) Protection of measles virus by sulfate ions against thermal inactivation. J Bacteriol 90:132–135PubMedPubMedCentral
12.
Waterson AP, Cruickshank JG, Laurence GD, Kanarek AD (1961) The nature of measles virus. Virology 15:379–382CrossRefPubMed
13.
Weil ML, Beard D, Sharp DG, Beard JW (1948) Purification, pH stability and culture of the mumps virus. J Immunol 60:561–582PubMed
14.
de las Mercedes Segura M, Kamen A, Garnier A (2006) Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 24:321–337CrossRef
15.
Rodrigues T, Carrondo MJT, Alves PM, Cruz PE (2007) Purification of retroviral vectors for clinical application: Biological implications and technological challenges. J Biotechnol 127:520–541CrossRefPubMed
16.
Burns JC, Friedmann T, Driever W et al (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90:8033–8037CrossRefPubMedPubMedCentral
17.
Beyer WR, Westphal M, Ostertag W, von Laer D (2002) Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 76:1488–1495CrossRefPubMedPubMedCentral
18.
Gatlin J, Melkus MW, Padgett A et al (2001) Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. J Virol 75:9995–9999CrossRefPubMedPubMedCentral
19.
Reiser J (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7:910–913CrossRefPubMed
20.
Njayou M, Quash G (1991) Purification of measles virus by affinity chromatography and by ultracentrifugation: a comparative study. J Virol Methods 32:67–77CrossRefPubMed
21.
Nestola P, Peixoto C, Silva RRJS et al. (2015) Improved virus purification processes for vaccines and gene therapy. Biotechnol Bioeng 112:843–857CrossRefPubMed
22.
Nayak DP, Lehmann S, Reichl U (2005) Downstream processing of MDCK cell-derived equine influenza virus. J Chromatogr B 823:75–81CrossRef
23.
Paul RW, Morris DAN, Hess BW et al (1993) Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther 4:609–615CrossRefPubMed
24.
Miller DL, Meikle PJ, Anson DS (1996) A rapid and efficient method for concentration of small volumes of retroviral supernatant. Nucleic Acids Res 24:1576–1577CrossRefPubMedPubMedCentral
25.
Segura MM, Puig M, Monfar M, Chillón M (2012) Chromatography purification of canine adenoviral vectors. Hum Gene Ther Methods 23:182–197CrossRefPubMed
26.
Nehring D, Poertner R, Schweizer M et al (2009) Integrated inline filtration: a method to produce highly concentrated retroviral vector titer supernatant. Desalination 245:614–620CrossRef
27.
Kotani H, Newton PB, Zhang S et al (1994) Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 5:19–28CrossRefPubMed
28.
Vicente T, Peixoto C, Carrondo MJT, Alves PM (2009) Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther 16:766–775CrossRefPubMed
29.
Makino M, Ishikawa G, Yamaguchi K et al (1994) Concentration of live retrovirus with a regenerated cellulose hollow fiber, BMM. Arch Virol 139:87–96CrossRefPubMed
30.
Kuiper M, Sanches RM, Walford JA, Slater NKH (2002) Purification of a functional gene therapy vector derived from moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol Bioeng 80:445–453CrossRefPubMed
31.
Maranga L, Rueda P, Antonis A et al (2002) Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 59:45–50CrossRefPubMed
32.
Papanikolaou E, Kontostathi G, Drakopoulou E et al (2013) Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation. Virus Res 175:1–11CrossRefPubMed
33.
Carr B, Wright M (2012) Nanoparticle tracking analysis: a review of applications and usage 2010–2012. Nanosight Ltd, pp 1–193
34.
Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27:796–810CrossRefPubMedPubMedCentral
35.
Forcic D, Košutić-Gulija T, Šantak M et al (2010) Comparisons of mumps virus potency estimates obtained by 50 % cell culture infective dose assay and plaque assay. Vaccine 28:1887–1892CrossRefPubMed
36.
World Health Organization (1997) Live measles virus vaccine. In: Manual of laboratory methods. Document WHO/VSQ/97.04. World Health Organization, Geneva, pp 79–82
37.
Dean RB, Dixon WJ (1951) Simplified statistics for small numbers of observations. Anal Chem 23:636–638CrossRef
38.
39.
Kissmann J, Ausar SF, Rudolph A et al (2008) Stabilization of measles virus for vaccine formulation. Hum Vaccin 4:350–359CrossRefPubMed
40.
Weil ML, Beard D, Beard JW (1948) pH stability, response to antibiotics and factors influencing egg-culture of mumps virus. Exp Biol Med 68:308–309CrossRef
41.
Leprat R, Aymard M (1979) Selective inactivation of hemagglutinin and neuraminidase on mumps virus. Arch Virol 61:273–281CrossRefPubMed
42.
Rani S, Gogoi P, Kumar S (2014) Spectrum of newcastle disease virus stability in gradients of temperature and pH. Biologicals 42:351–354CrossRefPubMed
43.
Moses HE, Brandly CA, Jones EE (1947) The pH stability of viruses of Newcastle disease and fowl plague. Science 105:477–479CrossRefPubMed
44.
Tolba MK, Eskarous JK (1959) pH-stability patterns of some strains of Newcastle disease and fowl-plague viruses. Arch Microbiol 34:333–338
45.
San Román K, Villar E, Munoz-Barroso I (1999) Acidic pH enhancement of the fusion of Newcastle disease virus with cultured cells. Virology 260:329–341CrossRefPubMed
46.
Schlehuber LD, McFadyen IJ, Shu Y et al (2011) Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay. Vaccine 29:5031–5039CrossRefPubMed
47.
48.
Lange C, Rudolph R (2009) Suppression of protein aggregation by L-arginine. Curr Pharm Biotechnol 10:408–414CrossRefPubMed
49.
Ejima D, Yumioka R, Arakawa T, Tsumoto K (2005) Arginine as an effective additive in gel permeation chromatography. J Chromatogr A 1094:49–55CrossRefPubMed
50.
Arakawa T, Philo JS, Tsumoto K et al (2004) Elution of antibodies from a protein-A column by aqueous arginine solutions. Protein Expr Purif 36:244–248CrossRefPubMed
51.
Katakam M, Bell LN, Banga AK (1995) Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84:713–716CrossRefPubMed
52.
Beauséjour Y, Tremblay MJ (2004) Interaction between the cytoplasmic domain of ICAM-1 and Pr55 Gag leads to acquisition of host ICAM-1 by human immunodeficiency virus type 1. J Virol 78:11916–11925CrossRefPubMedPubMedCentral
53.
Biswas M, Johnson JB, Kumar SRP et al (2012) Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J Virol 86:12708–12716CrossRefPubMedPubMedCentral
54.
55.
Franke EK, Yuan HE, Luban J (1994) Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359–362CrossRefPubMed
56.
Moyer SA, Baker SC, Horikami SM (1990) Host cell proteins required for measles virus reproduction. J Gen Virol 71:775–783CrossRefPubMed
57.
Shaw ML, Stone KL, Colangelo CM et al (2008) Cellular proteins in influenza virus particles. PLoS Pathog 4:1–13CrossRef
58.
Lotfian P, Levy MS, Coffin RS et al (2003) Impact of process conditions on the centrifugal recovery of a disabled herpes simplex virus. Biotechnol Prog 19:209–215CrossRefPubMed
59.
Zimmermann K, Scheibe O, Kocourek A et al (2011) Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnol 11:55–67CrossRefPubMedPubMedCentral
60.
Nestola P, Martins DL, Peixoto C et al (2014) Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration. PLoS One 9:e115802CrossRefPubMedPubMedCentral
Metadata
Title
Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus
Authors
Dora Sviben
Dubravko Forčić
Tihana Kurtović
Beata Halassy
Marija Brgles
Publication date
01-06-2016
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 6/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-016-2801-3

Other articles of this Issue 6/2016

Archives of Virology 6/2016 Go to the issue

Original Article

Lineage-specific detection of influenza B virus using real-time polymerase chain reaction with melting curve analysis

Original Article

Genotypic evolution and antigenicity of H9N2 influenza viruses in Shanghai, China

Original Article

Phylogenetic analysis of human influenza A/H3N2 viruses isolated in 2015 in Germany indicates significant genetic divergence from vaccine strains

Original Article

Identification of the subgenomic promoter of the coat protein gene of cucumber fruit mottle mosaic virus and development of a heterologous expression vector

Original Article

A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone

Original Article

Generation of E. coli-derived virus-like particles of porcine circovirus type 2 and their use in an indirect IgG enzyme-linked immunosorbent assay
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits